These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39134884)

  • 21. Topical anti-inflammatory treatments for eczema: network meta-analysis.
    Lax SJ; Van Vogt E; Candy B; Steele L; Reynolds C; Stuart B; Parker R; Axon E; Roberts A; Doyle M; Chu DK; Futamura M; Santer M; Williams HC; Cro S; Drucker AM; Boyle RJ
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015064. PubMed ID: 39105474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata.
    Tembunde Y; Kindred C
    J Drugs Dermatol; 2024 May; 23(5):378-379. PubMed ID: 38709705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.
    Kirito K; Okamoto S; Ohishi K; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Oritani K; Akashi K; Okada H; Amagasaki T; Suzuki K; Yonezu T; Komatsu N
    Int J Hematol; 2018 Jan; 107(1):92-97. PubMed ID: 28986762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.
    Ireland PA; Jansson N; Spencer SKR; Braden J; Sebaratnam D
    JAMA Dermatol; 2024 Mar; 160(3):281-289. PubMed ID: 38294793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
    Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
    J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
    [No Abstract]   [Full Text] [Related]  

  • 29. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs.
    Cao XC; Lu JW; Feng YF; Song LB; Lu Y
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4657-4662. PubMed ID: 38358466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
    Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
    J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
    Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
    J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib cream (Opzelura) for nonsegmental vitiligo.
    Med Lett Drugs Ther; 2022 Oct; 64(1660):158-159. PubMed ID: 36206166
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of fire needle combined with 308 nm excimer laser therapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials.
    Guo C; Gu X; Zhang J; Li J; Xu F; Wang Y; Zhang M; Zhang Y
    J Cosmet Dermatol; 2024 Aug; 23(8):2592-2602. PubMed ID: 38591186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-label studies on ruxolitinib in dermatology: a review.
    Wu J; Smogorzewski J
    J Dermatolog Treat; 2022 Mar; 33(2):606-612. PubMed ID: 32515635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.